Myoma;Uterus Clinical Trial
Official title:
Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy: a Randomized Controlled Trial
Submucous myomas represent one of the main indications of operative hysteroscopy. Since 1976 when Neuwirth and Amin reported the first five cases of excision of submucous myomas , several techniques have been developed in order to render hysteroscopic myomectomy a safe and effective procedure . Hysteroscopic myomectomy is currently considered the "gold standard" minimally invasive approach for the treatment of symptomatic submucous myomas . Patients undergoing hysteroscopic myomectomy are liable to significant blood loss, and hemodynamic and hematological disturbances. Excessive bleeding during hysteroscopic myomectomy remains a major challenge for the endoscopic gynecological surgeons. Many interventions were introduced to reduce the risk of bleeding during myomectomy. These include the use of utero-tonics such as oxytocin, or the use of anti-fibrinolytics such as tranexamic acid . The potential advantage of oxytocin infusion during hysteroscopic myomectomy is that it can maintains uterine contractility throughout the procedure, and thus, reduce blood loss . Carbetocin (1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin. When injected to a woman, it induces uterine contractions . Although many interventions have been described to reduce the intraoperative blood loss during hysteroscopic myomectomy, there is a need for a well-designed randomized controlled trials to identify the most efficient interventions, with reasonable safety profiles, to help the perform a safe and curative surgery.
All patients will have preoperative evaluation by gynecologists and anesthetists, with history taking and pelvic examination. A TVS scan will be done to determine the number, size and location of the myomas, and evaluate the myometrial free margin (the minimum thickness between the outer edge of the myoma and inner edge of the uterine serosa), which was found to be ideally ≥ 10 mm (11). Prior office diagnostic hysteroscopy will be performed for evaluation of the number, location and grade of the submucous myomas, and assessment of the endocervical canal and uterine cavity and the position of the tubal ostia in order to aid orientation. Preoperative full blood count, serum creatinine, fasting blood glucose, liver enzymes, coagulation profile ( INR), and viral markers will be done for all the patients. Monopolar resectoscopic myomectomies will be scheduled in the proliferative phase of menstrual cycle by a single experienced operator. After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of carbetocin (100 mcg/ml) IV over 1 minute (study group) or 1 ml of sodium chloride 0.9% IV over 1 minute (control group). The procedure will be done using the available standard setup and the distending solution used will be 1.5% glycine. A drape with a fluid-collection pouch (Lingeman 3 in 1 Procedure Drape, Lingeman Medical Products, Inc., Indianapolis, IN) placed beneath the woman's buttocks will be used to collect outflow fluid escaping between the cervix and sheath to prevent spillage of irrigating fluid onto the floor. Fluid inflow and outflow will be monitored every 3-5 minutes. The outflow fluid will be measured to the nearest milliliter. The inflow and outflow volumes of the distension solution will be carefully monitored continuously during the procedure by nurses not involved in the study under the current monitoring protocol at the operating theater. The procedure would be terminated if the fluid imbalance reached 1 L. After completing the procedure, the surgeon completed a record sheet for rating of bleeding amount and the quality of operative view. Postoperative full blood count will be done for all patients 24 hours after the procedures. Preoperative and postoperative hemoglobin and hematocrit, the need for blood transfusion, the duration of operation, any operative complications and medication adverse effects will be recorded. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04519593 -
ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma
|
N/A | |
Active, not recruiting |
NCT06114758 -
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
|
||
Not yet recruiting |
NCT05967936 -
Paracervical Block Versus Transcervical Block in Outpatient Procedural Hysteroscopy
|
N/A | |
Not yet recruiting |
NCT05932082 -
The Impact of Myomectomy on IVF Outcomes
|
N/A | |
Recruiting |
NCT04748978 -
OPPIuM Technique and Myolysis With Diode Laser Dwls
|
N/A | |
Recruiting |
NCT05271981 -
Fertility After Uterine Artery Embolization
|
||
Completed |
NCT05025410 -
Remimazolam and Remifentanil Without Neuromuscular Blocking Agent
|
||
Recruiting |
NCT03483142 -
the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation
|
Phase 3 | |
Completed |
NCT03533907 -
Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate.
|
||
Completed |
NCT05811286 -
The Use of a Morcellator in Operative Hysteroscopy for Benign Intracavitary Lesions: a Feasibility Study
|
N/A | |
Not yet recruiting |
NCT03570879 -
Laparoscopic Myomectomy With Morcellation or Transvaginal Extraction of Surgical Specimens.
|
||
Not yet recruiting |
NCT04364581 -
Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions
|
Phase 4 | |
Recruiting |
NCT06067971 -
Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery, by a Clinical Study During Gynecological Laparoscopic Surgical Procedures. (ENDORA2)
|
N/A | |
Recruiting |
NCT04990076 -
Ultrasound Evaluation of the Myometrium Using the MUSA Terminology Comparison With Histology
|
||
Recruiting |
NCT06325501 -
Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy
|
Phase 3 | |
Completed |
NCT05761418 -
Preoperative Vaginal Dinoprostone Versus Misoprostone in Abdominal Myomectomy
|
Phase 3 | |
Recruiting |
NCT04311073 -
Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies
|
Phase 3 | |
Active, not recruiting |
NCT05930769 -
Retrospective Study on the Evaluation of the Impact of Augmented Reality Usage in Gynecological Laparoscopy on Patients Operated Between 2017 and 2021 (ImpactRA)
|
||
Recruiting |
NCT03550703 -
Open Label Immunotherapy of Myoma
|
Phase 2 | |
Not yet recruiting |
NCT04030273 -
Prevalence of Intrauterine Adhesions After Abdominal Myomectomy
|